Skip to content
  • ul. Na Zaspa 3, 80-546, Gdańsk
  • pihouse@pihouse.pl
  • +48 58 719 22 22
  • START
  • About PI-House
  • CLINIC
  • Contact
Menu
  • START
  • About PI-House
  • CLINIC
  • Contact
Search
close

The institution is closed from 25.07-29.07. We apologize for inconveniences.

  • Post author:admin-ns6cgF
  • Post published:25 June 2019
  • Post category:Alert

Continue ReadingThe institution is closed from 25.07-29.07. We apologize for inconveniences.

General information

Centrum Badań Klinicznych PI-House sp. z o. o.
NIP: 9571059089 | EU VAT ID: PL9571059089
REGON: 221506777 | KRS: 0000394618
Share capital: PLN 60,000
Entry number in the Register of
Health Care Providers: 000000154510

 

Data Protection – find out more..

Contact

  • ul. Na Zaspę 3,
    80-546 Gdańsk
  • +48 58 719 22 22
  • FAX: +48 58 719 22 21
  • pihouse@pihouse.pl
  • rejestracja@pihouse.pl

CBK PI-HOUSE

  • START
  • About PI-House
  • CLINIC
  • Contact
Menu
  • START
  • About PI-House
  • CLINIC
  • Contact
en_GBEnglish (UK)
pl_PLPolski en_GBEnglish (UK)

Study 1

RETURN

Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression

Therapeutic area: Treatment-resistant depressive disorder

Phase: III

Start Date: June 9, 2016

End date: December 31, 2022

Status: Not recruiting

Sponsor Name: Janssen Research & Development, LLC

Study 1

RETURN

Study title: Long-term, multicentre, randomized, double-blind, controlled, parallel group study of the safety and efficacy of Lemborekxant in people with insomnia disorders

Therapeutic area: Disorder of insomnia

Phase: III

Start Date: November 15, 2016 

End date: January 8, 2019

Status: Not recruiting

Sponsor Name: Eisai Inc.

Study 1

RETURN

Study title: Adaptive, multicentre, prospective, randomized, double-blind, placebo-controlled phase IIb / III study of the safety and efficacy of NaBen® (DAAO inhibitor) as an additional treatment for schizophrenia in adults

Therapeutic area: schizophrenia

Phase: IIb / III

Start Date: March 29, 2017

End date: December 31, 2021

Status: Recruiting 

Sponsor Name: SyneuRx

Study 2

RETURN

Study title: Adaptive Phase II / III study, two-part, double-blind, randomized, placebo-controlled, dose-titled multicenter study of the safety and efficacy of NaBen® as add-on therapy with clozapine for the treatment of symptoms of refractory schizophrenia in adults

Therapeutic area: schizophrenia

Phase: II / III

Start Date: March 29, 2017

End date: December 31, 2021

Status: Recruiting 

Sponsor Name: SyneuRx

Ta strona korzysta z ciasteczek aby świadczyć usługi na najwyższym poziomie. Dalsze korzystanie ze strony oznacza, że zgadzasz się na ich użycie. Aby przeczytać więcej, zobacz naszą polityke prywatności.AgreementPolityka prywatności